Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

Original Submission
25 Feb 2020 Submitted Original manuscript
19 Apr 2020 Reviewed Reviewer Report - Carlo Garufi
17 Jun 2020 Reviewed Reviewer Report
9 Jul 2020 Author responded Author comments - Zhi Peng
Resubmission - Version 2
9 Jul 2020 Submitted Manuscript version 2
12 Jul 2020 Reviewed Reviewer Report
30 Sep 2020 Author responded Author comments - Zhi Peng
Resubmission - Version 3
30 Sep 2020 Submitted Manuscript version 3
Publishing
2 Oct 2020 Editorially accepted
13 Oct 2020 Article published 10.1186/s12885-020-07486-w

You can find further information about peer review here.

Back to article page